Leerink Partnrs Predicts Stronger Earnings for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued on Thursday, November 21st. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($2.19) for the year, up from their prior estimate of ($2.51). The consensus estimate for Kura Oncology's current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Kura Oncology's Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

A number of other equities analysts also recently issued reports on the company. Lifesci Capital upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. Wedbush reiterated an "outperform" rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities restated a "market outperform" rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. StockNews.com downgraded shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Wednesday, November 20th. Finally, TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $29.38.

Kura Oncology Stock Up 1.5 %

Shares of NASDAQ:KURA traded up $0.16 during trading on Monday, hitting $10.96. The stock had a trading volume of 3,977,759 shares, compared to its average volume of 1,007,373. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $9.06 and a 12 month high of $24.17. The company has a market capitalization of $852.25 million, a PE ratio of -4.64 and a beta of 0.86. The firm's fifty day moving average is $17.88 and its 200 day moving average is $19.67.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in shares of Kura Oncology in the third quarter worth about $25,000. SG Americas Securities LLC purchased a new position in Kura Oncology during the first quarter worth $110,000. Point72 DIFC Ltd purchased a new position in shares of Kura Oncology during the 3rd quarter worth about $146,000. Quarry LP bought a new stake in Kura Oncology in the second quarter worth about $196,000. Finally, Erste Asset Management GmbH purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.